Leaderboards/Prostate Cancer Diagnosis and Treatment

Prostate Cancer Diagnosis and Treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Tyler B. Kratzer
American Cancer Society
2
Anindo Saha
Radboud University Nijmegen
3
Elizabeth J. Schafer
American Cancer Society
4
Jana McHugh
Institute of Cancer Research
5
Cameron Englman
University College London Hospitals NHS Foundation Trust
6
Eoin Dinneen
Peter MacCallum Cancer Centre
7
Ivo I. de Vos
Erasmus MC Cancer Institute
8
Haifan Gong
Chinese University of Hong Kong, Shenzhen
9
Mikel Byrne
Cancer Council Queensland
10
Karolína Guricová
Radboud University Nijmegen

Papers

1
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
The Lancet Oncology|2024
273 cit.
2
Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update
European Urology|2024
189 cit.
3
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer
New England Journal of Medicine|2025
77 cit.
4
Nnmamba: 3D Biomedical Image Segmentation, Classification and Landmark Detection with State Space Model
Unknown Journal|2025
59 cit.
5
Publication in European Urology (2024) [58 citations, W4393334202]
European Urology|2024
58 cit.
6
Prostate cancer statistics, 2025
CA A Cancer Journal for Clinicians|2025
55 cit.
7
Publication in The Lancet Oncology (2025) [42 citations, W4408773627]
The Lancet Oncology|2025
42 cit.
8
Publication in European Urology (2025) [18 citations, W4410765341]
European Urology|2025
18 cit.
9
Publication in European Urology (2024) [8 citations, W4392765478]
European Urology|2024
8 cit.
10
Publication in British Journal of Urology (2025) [7 citations, W4409408028]
British Journal of Urology|2025
7 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Geert Litjens
Radboud University Nijmegen
2
Nikhil Babu Oommen
Unknown
3
Charlotte F. Kweldam
Maasstad Ziekenhuis
4
Tobias Nordström
Karolinska Institutet
5
Brent S. Rose
University of San Diego
6
Maria Vilarino-Varela
Institute of Cancer Research
7
Deanna Saunders
Ottawa Hospital
8
M. Panadés
United Lincolnshire Hospitals NHS Trust
9
Veeru Kasivisvanathan
University College London Hospitals NHS Foundation Trust
10
Constantinos Zamboglou
University Hospitals of Cleveland

Papers

1
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
The Lancet Oncology|2022
303 cit.
2
Predictive uncertainty estimation for out-of-distribution detection in digital pathology
Medical Image Analysis|2022
70 cit.
3
Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol
BMJ Open|2023
67 cit.
4
PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01)
International Journal of Radiation Oncology*Biology*Physics|2022
44 cit.
5
Automatic data augmentation to improve generalization of deep learning in H&E stained histopathology
Computers in Biology and Medicine|2024
44 cit.
6
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
JAMA Oncology|2022
43 cit.
7
Predicting biochemical recurrence of prostate cancer with artificial intelligence
Communications Medicine|2022
39 cit.
8
Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities
JAMA Oncology|2022
35 cit.
9
Diffusion models for out-of-distribution detection in digital pathology
Medical Image Analysis|2024
33 cit.
10
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy
International Journal of Radiation Oncology*Biology*Physics|2022
32 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Peter R. Carroll
University of California, San Francisco
2
Peter T. Scardino
Memorial Sloan Kettering Cancer Center
3
Jonathan I. Epstein
Johns Hopkins University
4
William J. Catàlona
Northwestern University
5
Howard M. Sandler
Cedars-Sinai Medical Center
6
Anssi Auvinen
Tampere University of Applied Sciences
7
Mark Emberton
University College London
8
Pierre I. Karakiewicz
Université de Montréal
9
Jelle O. Barentsz
Netherlands Leprosy Relief
10
Peter A. Pinto
National Institutes of Health

Papers

1
Screening and Prostate-Cancer Mortality in a Randomized European Study
New England Journal of Medicine|2009
4k cit.
2
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
The Lancet|2017
3.2k cit.
3
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
International Journal of Radiation Oncology*Biology*Physics|2006
2.7k cit.
4
ESUR prostate MR guidelines 2012
European Radiology|2012
2.4k cit.
5
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
New England Journal of Medicine|1991
2.4k cit.
6
Why Do Parents Become Involved in Their Children’s Education?
Review of Educational Research|1997
1.7k cit.
7
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
The Lancet|2014
1.6k cit.
8
Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer
JAMA|2015
1.5k cit.
9
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men
The Journal of Urology|1994
1.4k cit.
10
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
European Urology|2015
1.4k cit.

Reagents for Prostate Cancer Diagnosis and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Synaptophysin (7H12) Mouse Monoclonal Antibody (BSA and Azide Free)

Cited in 6 papers
#36451$865
View Evidence →
Cell Signaling Technology

PINCH (5G7) Mouse Monoclonal Antibody

Cited in 5 papers
#11890$158,348
View Evidence →
Millipore

Anti-Androgen Receptor, PG-21

#06-680
View Evidence →

🌟 All-Time

Most validated

Cytek Biosciences

PE Anti-Mouse CD274 (PD-L1, B7-H1) (10F.9G2)

Cited in 20 papers
#50-1243
View Evidence →
Cell Signaling TechnologyEvidence 66

Tyrosine Hydroxylase (E2L6M) Feline Chimeric Monoclonal Antibody

Cited in 14 papers
#69079$166,369
View Evidence →
Agilent/Dako

Prostate Specific Antigen Membrane Antigen

Cited in 12 papers
#M3620
View Evidence →